Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

3 terminated/withdrawn out of 24 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 1
12(57.1%)
Early Phase 1
5(23.8%)
Phase 2
4(19.0%)
21Total
Phase 1(12)
Early Phase 1(5)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT07275736Early Phase 1Recruiting

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

Role: lead

NCT03029338Phase 1Completed

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Role: collaborator

NCT06676982Phase 1Recruiting

Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

Role: collaborator

NCT07265206Early Phase 1Not Yet Recruiting

A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

Role: lead

NCT07091370Phase 1Not Yet Recruiting

Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy

Role: lead

NCT05667506Phase 1Recruiting

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Role: lead

NCT06009107Phase 1Withdrawn

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Role: lead

NCT04684147Phase 2Recruiting

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Role: lead

NCT06005649Phase 1Withdrawn

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Role: lead

NCT06461351Recruiting

Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

Role: lead

NCT06826430Phase 1Recruiting

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

Role: lead

NCT04008524Unknown

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Role: collaborator

NCT02975687Phase 1Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Role: collaborator

NCT04034446Early Phase 1Terminated

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Role: collaborator

NCT06231368Phase 1Active Not Recruiting

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Role: collaborator

NCT04690192Phase 1Completed

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Role: collaborator

NCT06316791Early Phase 1Recruiting

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Role: lead

NCT04586478Phase 2Recruiting

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: lead

NCT06608732Phase 2Recruiting

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Role: collaborator

NCT06608342Phase 2Recruiting

Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Role: collaborator